158 related articles for article (PubMed ID: 9365520)
21. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression.
Xu F; Yu Y; Le XF; Boyer C; Mills GB; Bast RC
Clin Cancer Res; 1999 Nov; 5(11):3653-60. PubMed ID: 10589783
[TBL] [Abstract][Full Text] [Related]
22. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.
Wallasch C; Weiss FU; Niederfellner G; Jallal B; Issing W; Ullrich A
EMBO J; 1995 Sep; 14(17):4267-75. PubMed ID: 7556068
[TBL] [Abstract][Full Text] [Related]
23. Study of inhibition effect of herceptin on interaction between heregulin and erbB receptors HER3/HER2 by single-molecule force spectroscopy.
Shi X; Xu L; Yu J; Fang X
Exp Cell Res; 2009 Oct; 315(16):2847-55. PubMed ID: 19497323
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3.
Chen CH; Chernis GA; Hoang VQ; Landgraf R
Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9226-31. PubMed ID: 12874383
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
26. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.
Alimandi M; Romano A; Curia MC; Muraro R; Fedi P; Aaronson SA; Di Fiore PP; Kraus MH
Oncogene; 1995 May; 10(9):1813-21. PubMed ID: 7538656
[TBL] [Abstract][Full Text] [Related]
27. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.
Pinkas-Kramarski R; Soussan L; Waterman H; Levkowitz G; Alroy I; Klapper L; Lavi S; Seger R; Ratzkin BJ; Sela M; Yarden Y
EMBO J; 1996 May; 15(10):2452-67. PubMed ID: 8665853
[TBL] [Abstract][Full Text] [Related]
28. Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-beta2/PE40.
Furger C; Fiddes RJ; Quinn DI; Bova RJ; Daly RJ; Sutherland RL
Cancer Res; 1998 May; 58(9):1773-8. PubMed ID: 9581810
[TBL] [Abstract][Full Text] [Related]
29. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
Sakai K; Yokote H; Murakami-Murofushi K; Tamura T; Saijo N; Nishio K
Cancer Sci; 2007 Sep; 98(9):1498-503. PubMed ID: 17627612
[TBL] [Abstract][Full Text] [Related]
30. Role of epidermal growth factor receptor family members in growth and differentiation of breast carcinoma.
Cohen BD; Siegall CB; Bacus S; Foy L; Green JM; Hellström I; Hellström KE; Fell HP
Biochem Soc Symp; 1998; 63():199-210. PubMed ID: 9513724
[TBL] [Abstract][Full Text] [Related]
31. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix.
Lee CM; Shrieve DC; Zempolich KA; Lee RJ; Hammond E; Handrahan DL; Gaffney DK
Gynecol Oncol; 2005 Nov; 99(2):415-21. PubMed ID: 16157365
[TBL] [Abstract][Full Text] [Related]
32. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.
Steffensen KD; Waldstrøm M; Andersen RF; Olsen DA; Jeppesen U; Knudsen HJ; Brandslund I; Jakobsen A
Int J Oncol; 2008 Jul; 33(1):195-204. PubMed ID: 18575766
[TBL] [Abstract][Full Text] [Related]
33. The EGF receptor family--multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4.
Earp HS; Calvo BF; Sartor CI
Trans Am Clin Climatol Assoc; 2003; 114():315-33; discussion 333-4. PubMed ID: 12813928
[TBL] [Abstract][Full Text] [Related]
34. HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4).
Sollome JJ; Thavathiru E; Camenisch TD; Vaillancourt RR
Cell Signal; 2014 Jan; 26(1):70-82. PubMed ID: 24036211
[TBL] [Abstract][Full Text] [Related]
35. The epidermal growth factor family has a dual role in deciding the fate of cancer cells.
Memon AA; Sorensen SB; Nexo E
Scand J Clin Lab Invest; 2006; 66(7):623-30. PubMed ID: 17101554
[TBL] [Abstract][Full Text] [Related]
36. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells.
Sartor CI; Zhou H; Kozlowska E; Guttridge K; Kawata E; Caskey L; Harrelson J; Hynes N; Ethier S; Calvo B; Earp HS
Mol Cell Biol; 2001 Jul; 21(13):4265-75. PubMed ID: 11390655
[TBL] [Abstract][Full Text] [Related]
37. Role of HER2/HER3 co-receptor in breast carcinogenesis.
Way TD; Lin JK
Future Oncol; 2005 Dec; 1(6):841-9. PubMed ID: 16556064
[TBL] [Abstract][Full Text] [Related]
38. Tyrosine phosphorylation of PYK2 mediates heregulin-induced glioma invasion: novel heregulin/HER3-stimulated signaling pathway in glioma.
van der Horst EH; Weber I; Ullrich A
Int J Cancer; 2005 Feb; 113(5):689-98. PubMed ID: 15499613
[TBL] [Abstract][Full Text] [Related]
39. Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3.
Chan SD; Antoniucci DM; Fok KS; Alajoki ML; Harkins RN; Thompson SA; Wada HG
J Biol Chem; 1995 Sep; 270(38):22608-13. PubMed ID: 7673253
[TBL] [Abstract][Full Text] [Related]
40. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.
Gregory CW; Whang YE; McCall W; Fei X; Liu Y; Ponguta LA; French FS; Wilson EM; Earp HS
Clin Cancer Res; 2005 Mar; 11(5):1704-12. PubMed ID: 15755991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
